Ocugen, Inc. financial data

Symbol
OCGN on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
11 Great Valley Parkway, Malvern, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
HISTOGENICS CORP (to 9/26/2019)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 198 % -37.2%
Debt-to-equity 70.4 % +44.7%
Return On Equity -159 % -32.6%
Return On Assets -93.5 % -15.6%
Operating Margin -1.12K % +20.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 291M shares +13.6%
Common Stock, Shares, Outstanding 290M shares +13.2%
Entity Public Float 137M USD -71.6%
Common Stock, Value, Issued 2.9M USD +13.2%
Weighted Average Number of Shares Outstanding, Basic 257M shares +7.99%
Weighted Average Number of Shares Outstanding, Diluted 257M shares +7.99%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.7M USD -14.6%
General and Administrative Expense 25.5M USD -24.6%
Operating Income (Loss) -52.4M USD +32.2%
Nonoperating Income (Expense) 1.3M USD -54.6%
Net Income (Loss) Attributable to Parent -51.1M USD +31.4%
Earnings Per Share, Basic -0.17 USD/shares +56.4%
Earnings Per Share, Diluted -0.17 USD/shares +56.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.7M USD -77.8%
Assets, Current 40.7M USD -28.1%
Property, Plant and Equipment, Net 17.1M USD +18.4%
Operating Lease, Right-of-Use Asset 3.94M USD +0.87%
Other Assets, Noncurrent 3.83M USD +4.59%
Assets 61.9M USD -17.1%
Accounts Payable, Current 1.49M USD -48.9%
Employee-related Liabilities, Current 2.04M USD -28.6%
Liabilities, Current 15.8M USD -20.1%
Operating Lease, Liability, Noncurrent 3.42M USD +8.06%
Other Liabilities, Noncurrent 554K USD +11.5%
Liabilities 21.3M USD -14.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD -14.8%
Retained Earnings (Accumulated Deficit) -326M USD -18.6%
Stockholders' Equity Attributable to Parent 40.6M USD -18.4%
Liabilities and Equity 61.9M USD -17.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.6M USD +41.9%
Net Cash Provided by (Used in) Financing Activities -145K USD -103%
Net Cash Provided by (Used in) Investing Activities -2.35M USD -168%
Common Stock, Shares Authorized 390M shares +32.2%
Common Stock, Shares, Issued 290M shares +13.2%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -13.1M USD -40.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 39M USD -27.1%
Deferred Tax Assets, Valuation Allowance 112M USD +17.4%
Deferred Tax Assets, Gross 113M USD +17.2%
Operating Lease, Liability 3.9M USD +5.18%
Payments to Acquire Property, Plant, and Equipment 2.35M USD +45.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.1M USD +31.4%
Lessee, Operating Lease, Liability, to be Paid 5.36M USD +20.7%
Property, Plant and Equipment, Gross 19.7M USD +26.9%
Operating Lease, Liability, Current 477K USD -11.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 869K USD +7.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 845K USD +7.37%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +46.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.46M USD +99.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 867K USD +3.96%
Deferred Tax Assets, Operating Loss Carryforwards 58.3M USD +19.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 303K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 884K USD +6%
Additional Paid in Capital 364M USD +12.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 918K USD -5.85%
Share-based Payment Arrangement, Expense 7.27M USD -28.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%